西酞普兰治疗持续性躯体形式疼痛障碍对照研究

目的：观察西酞普兰治疗持续性躯体形式疼痛障碍的疗效。方法：将持续性躯体形式疼痛障碍门诊患者64例随机分为治疗组和对照组，两组分别给予西酞普兰（31人）和阿米替林（33人）治疗，总疗程6周。分别于治疗前及治疗后第2、4、6周评定疗效，阿米替林组有2例脱漏，最后完成疗程每组各31人。结果：治疗组和对照组完全缓解分别为9例和8例，明显缓解分别为10例和8例，轻度缓解分别为7例和9例，无效分别为5例和6例；有效率分别为83．87％，80．65％；两组间差异无显著性（P〉0．05）。但治疗组口干、便秘、视物模糊、心动过速、嗜睡等不良反应明显比对照组少（P〈0．01）。结论：西酞普兰对持续性躯体形式疼痛障碍与阿米替林疗效相当，但不良反应小。

COMPARATIVE STUDY OF CITALOPRAM IN THE TREATMENT OF PERSISTENT SOMATOFORM PAIN DISORDER

Objective:To study the effects of citalopram in the persistent somatoform pain disorder. Methods: 64 outpatients were randomly divided into the treatment (citalopram) group(n=31)and control(amitryptiline) group(n=33). Patients of the treatment and control groups were given citalopram and amityptiline respectively. Results: The effective rates of the treatment and control groups were 83.87% and 80.65% respectively, and the difference was not significant (P>0.05). However, the incidence of adverse reactions including xerostomia, constipation, blurred vision, tachycardia and somnolence was significantly lower in the treatment group than that in the control group (P<0.01). Conclusion: Citalopram was effective and safe in the treatment of persistent somatoform pain disorder with a low incidence of adverse reactions.